Life Sciences

Pfizer to settle Bextra, Celebrex claims for $894M

Pharma Compliance Alert, October 22, 2008

Pfizer has agreed in principle to pay $894 million to settle all lawsuits related to its non-steroidal anti-inflammatory drugs Bextra and Celebrex, according to a company release.

The settlement covers more than 90% of the personal injury lawsuits filed by patients who claim the drugs caused a heart attack, stroke, or other injury. The settlement also resolves payer class action consumer fraud cases involving Bextra and Celebrex in which plaintiffs allege economic loss relating to the promotion of these medications.

Pfizer also reached an agreement to settle claims by 33 states and the District of Columbia relating to alleged marketing practices for Bextra.

Comments

3 comments on “Pfizer to settle Bextra, Celebrex claims for $894M

Linda Shelton (6/1/2009 at 3:11 PM)
I also would like more information on the lawsuit. I was diagnosed in May of 1998 with fibromyalgia, bi-lateral carpal tunnel syndrome and bi-lateral thoracic outlet syndrome. Celebrex was prescribed for pain relief but even with insurance co-pay, the product was too expensive to use. Please send more info on the lawsuit. Thank you.

 

    Healthcare Life Safety Compliance
  • Healthcare Life Safety Compliance

    Learn Life Safety Code tips and interpretations for healthcare facilities with this in-depth monthly resource.

  • Briefings on Infection Control

    Your facility's infection control and prevention initiatives are in the spotlight: Scrutiny from The Joint Commission, CDC...

  • ePharm5 InDepth

    EPharm5 e-mail newsletter delivers the top 5 developments in pharma business innovation, with original research, interviews...

  • Medical Environment Update

    Timely medical compliance news from OSHA, CDC, EPA, and other regulatory agencies!

  • OSHA Regulatory Manual for Healthcare

    The OSHA Regulatory Manual for Healthcare is packed with clear, concise tips, tools, and strategies that are designed to...

Most Popular

Related Articles